Bristol-Myers Squibb Co (BMY) Shares Sold by Cullinan Associates Inc.

Cullinan Associates Inc. lessened its position in Bristol-Myers Squibb Co (NYSE:BMY) by 5.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 77,250 shares of the biopharmaceutical company’s stock after selling 4,150 shares during the quarter. Cullinan Associates Inc.’s holdings in Bristol-Myers Squibb were worth $4,015,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. New England Research & Management Inc. increased its stake in shares of Bristol-Myers Squibb by 48.5% during the 4th quarter. New England Research & Management Inc. now owns 23,417 shares of the biopharmaceutical company’s stock worth $1,217,000 after purchasing an additional 7,650 shares during the last quarter. Carroll Financial Associates Inc. increased its stake in shares of Bristol-Myers Squibb by 1.5% during the 4th quarter. Carroll Financial Associates Inc. now owns 17,024 shares of the biopharmaceutical company’s stock worth $824,000 after purchasing an additional 248 shares during the last quarter. First Hawaiian Bank increased its stake in shares of Bristol-Myers Squibb by 16.6% during the 4th quarter. First Hawaiian Bank now owns 34,919 shares of the biopharmaceutical company’s stock worth $1,816,000 after purchasing an additional 4,984 shares during the last quarter. State of Alaska Department of Revenue increased its stake in shares of Bristol-Myers Squibb by 1.6% during the 4th quarter. State of Alaska Department of Revenue now owns 242,890 shares of the biopharmaceutical company’s stock worth $12,622,000 after purchasing an additional 3,885 shares during the last quarter. Finally, Retirement Systems of Alabama increased its stake in shares of Bristol-Myers Squibb by 97.8% during the 4th quarter. Retirement Systems of Alabama now owns 1,488,554 shares of the biopharmaceutical company’s stock worth $77,375,000 after purchasing an additional 736,000 shares during the last quarter. Institutional investors and hedge funds own 72.68% of the company’s stock.

NYSE:BMY opened at $47.99 on Friday. Bristol-Myers Squibb Co has a 1 year low of $44.30 and a 1 year high of $70.05. The company has a current ratio of 1.53, a quick ratio of 1.40 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $77.01 billion, a P/E ratio of 15.94, a PEG ratio of 1.29 and a beta of 0.98.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.18. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Bristol-Myers Squibb had a net margin of 6.50% and a return on equity of 47.89%. Research analysts forecast that Bristol-Myers Squibb Co will post 3.88 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, February 1st. Shareholders of record on Friday, January 4th will be given a $0.41 dividend. This represents a $1.64 annualized dividend and a yield of 3.42%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. The ex-dividend date is Thursday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 54.49%.

BMY has been the topic of several analyst reports. Citigroup lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $62.00 to $57.00 in a research note on Monday, October 22nd. JPMorgan Chase & Co. increased their price target on shares of Bristol-Myers Squibb from $70.00 to $74.00 and gave the stock an “overweight” rating in a research note on Monday, October 8th. Credit Suisse Group restated a “hold” rating and set a $59.00 price target on shares of Bristol-Myers Squibb in a research note on Thursday, December 13th. William Blair restated an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Monday, October 22nd. Finally, Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, October 1st. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $61.56.

ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Co (BMY) Shares Sold by Cullinan Associates Inc.” was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.thestockobserver.com/2019/01/12/bristol-myers-squibb-co-bmy-shares-sold-by-cullinan-associates-inc.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Read More: Risk Tolerance

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply